Dr. Golubovskaya received her Ph.D. from the Institute of Cytology, St. Petersburg, Russia. After a post-doctoral fellowship in St. Jude Children's Hospital and Lineberger Comprehensive Cancer Center, she joined the Department of Surgery, as a Research Assistant Professor in Gainesville, FL. In 2009 she became an Associate Professor of Surgical Oncology at Roswell Park Cancer Institute, Buffalo, NY. She was a recipient and Principal Investigator of Susan G. Komen Grant for the Cure on Breast Cancer Research, Co-Investigator of RO-1 grant from NCI and recipient of STTR grant from NCI. She was a Member of the Graduate Programs at University of Buffalo SUNY, Buffalo, NY and Roswell Park Cancer (RPCI) Institute and Experimental Therapeutics Program at RPCI. She has published more than 75 peer-reviewed papers in prestigious journals such as Science Signaling, Elife, Cancer Research, Oncogene, Cell Cycle, JBC and Molecular Targets and Cancer Therapeutics. Currently, she is Director of Business Development and Research at Promab Biotechnologies directing scientific Program on novel anti-cancer immunotherapies (CAR-T).
Dr. Vita Golubovskaya research interests are intracellular signaling of cancer such as growth factor receptors, angiogenesis receptors, Focal Adhesion Kinase, Src, PI3K, AKT and WNT signaling. In addition, resistance of cancer cells to therapies and mechanism of overcoming this resistance is a key for developing novel anti-cancer therapies. The mechanism of cancer stem cell signaling and heterogeneity of tumor, circulating tumor cells and mechanisms of metastasis are also important area of research. Recently, He started to develop immunotherapy approaches against cancer cells using chimeric antigen receptor (CAR)-T cells. CAR-T therapy is a highly effective type of immunotherapy against hematological cancers and also solid tumors. The challenges of CAR-T therapy against solid tumors is to overcome immune checkpoint inhibition, microenvironment inhibitory signaling, to increase its safety that will be developed in future.